Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 16/20 | 0.98 |
| ▸ | CCND1 | P24385 | 15/20 | 0.98 |
| ▸ | CDK2 | P24941 | 13/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.98 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.98 |
| ▸ | CDK1 | P06493 | 4/20 | 0.98 |
| ▸ | NUAK1 | O60285 | 4/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.98 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.98 |
| ▸ | MARK3 | P27448 | 2/20 | 0.98 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.98 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.98 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.98 |
| ▸ | MARK1 | Q9P0L2 | 2/20 | 0.98 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.98 |
| ▸ | CDK7 | P50613 | 2/20 | 0.98 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.98 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Narazaciclib SCHEMBL30418763 | 0.99 | CDK4 (1.00) | CDK4CCND1CDK2CCNA2FGFR1 | |
| Narazaciclib SCHEMBL10050883 | 0.99 | CDK4 (1.00) | CDK4CCND1CDK2CCNA2FGFR1 | |
| Narazaciclib SCHEMBL14955407 | 0.98 | CDK4 (0.98) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14954855 | 0.97 | CDK4 (0.97) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14955588 | 0.96 | CDK4 (0.93) | CDK4CCND1CDK2CCNA2FGFR1 | |
| Narazaciclib SCHEMBL26685640 | 0.95 | CDK4 (0.92) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL24618846 | 0.95 | CDK4 (0.92) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22164862 | 0.93 | CDK4 (0.89) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22860493 | 0.92 | CDK4 (0.87) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL22860695 | 0.92 | CDK4 (0.87) | CDK4CCND1CDK2CCNA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987267-B2 | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | claimed |
| EP-2600719-B1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | UNIV TEMPLE (US) | 2014-10-08 | — | — | EP | claimed |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-05-23 | — | — | US | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| US-20160008316-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (CA) | 2016-01-14 | — | — | US | disclosed |
| US-8987267-B2 | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987267-B2 | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987267-B2 | 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2600719-B1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | UNIV TEMPLE (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2600719-B1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | UNIV TEMPLE (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-05-23 | — | — | US | disclosed |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-05-23 | — | — | US | disclosed |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | CDK4 129/4885CCND1 273/4885CDK2 398/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | CDK4 129/4885CCND1 273/4885CDK2 398/4885 |
| US-20160008316-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | CDK4 129/4885CCND1 273/4885CDK2 398/4885 |
| US-20130131058-A1 | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D] PYRIMIDINE-6-CARBONITRILES AND USES THEREOF | CDK7, CDK2, CDK8 | CDK4 11/4885CCND1 99/4885CDK2 2/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | CDK4 129/4885CCND1 273/4885CDK2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.